Mr. Dane Stevens reports

OPTIMI HEALTH COMPLETES FIRST 2026 PRODUCTION OF MDMA AND PSILOCYBIN CAPSULES

Optimi Health Corp. has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme.

The completed batch consists of 1,000 MDMA capsules in a 60-milligram dosage form and 1,000 naturally derived psilocybin capsules in a five mg dosage form. Final packaging, labelling and batch release were completed in accordance with Optimi's drug establishment licence issued by Health Canada. The capsules are good-manufacturing-practice-compliant and supported by Certificates of Analysis confirming conformance with applicable quality specifications, following receipt of the required Australian import permits.

"This production run has been released and approved for import, allowing Optimi to continue supplying MDMA and psilocybin into Australia's regulated health care system," said Dane Stevens, chief executive officer of Optimi Health. "Completing this first production cycle of 2026 positions us to expand access across the country for patients suffering from PTSD and TRD."

Posttraumatic stress disorder (PTSD) and treatment-resistant depression (TRD) represent significant unmet medical needs in Australia. National data published by the Australian Bureau of Statistics indicate that approximately 5 to 6 per cent of Australians experience PTSD in a given year, representing roughly 1.3 million to 1.5 million people. According to the Australian Institute of Health and Welfare, more than 1.3 million Australians are affected by depressive disorders, and clinical research suggests that around one-third of individuals with major depressive disorder do not respond adequately to standard treatments.

Australian clinics, hospital networks and programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at info@mindmedicineaustralia.org. For global inquiries outside of Australia, please contact the company at sales@optimihealth.ca.

About Optimi Health Corp.

Optimi Health is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP-compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the special access program.

We seek Safe Harbor.